| Ytd | -33.69% | |
| 1y | -45.41% |
| Open | 1.02 | Prev Close | 1.01 | Low | 0.97 | High | 1.04 | Mkt Cap | 125.73M |
| Vol | 429.64K | Avg Vol | 539.21K | EPS | -0.16 | P/E | N/A | Forward P/E | -13.63 |
| Beta | 0.18 | Short Ratio | 0.57 | Inst. Own | 1.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-08 | 50-d Avg | 1.10 | 200-d Avg | 1.35 | 1yr Est | 3.00 |
TLSA News
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANY
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnol
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or t
Polymarket, the crypto-based prediction platform, puts the probability of no new Gemini Pro release
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO Ivor Elrifi increased his stake in the company
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or t
Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ:TLSA) on Friday revealed promising quantitativ
Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with mul
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing it
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with mul
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or t
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has rec
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, pl
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, pl
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechno
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or t
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a b
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will present at the Jefferies Global Healthcare Conf
UBS is sticking with a Buy rating on FedEx Corp (NYSE:FDX, XETRA:FDX) and a price target of $445, as
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evalu
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evalu
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Ph
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing i
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing it
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing it
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing i
The poster, titled "A Phase 2a Study of Intranasal Foralumab in Multiple System Atrophy," wi
Tiziana Life Sciences shares jump on intranasal foralumab data, while technical indicators point to
U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four in
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company